Dines Alison M, Wood David M, Galicia Miguel, Yates Christopher M, Heyerdahl Fridtjof, Hovda Knut Erik, Giraudon Isabelle, Sedefov Roumen, Dargan Paul I
Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, Westminster Bridge Road, SE1 7EH, London, UK.
King's College London, London, UK.
J Med Toxicol. 2015 Dec;11(4):415-21. doi: 10.1007/s13181-014-0460-x.
Cannabis is the most commonly used illicit drug in Europe, and is generally regarded as having low acute toxicity. We present the findings of the first 6 months of data collection from the Euro-DEN project on presentations related to cannabis use to further understand the acute toxicity related to the use of cannabis. Data was extracted on clinical features, treatment and outcome from the Euro-DEN minimum dataset for all cases of acute recreational drug toxicity reported 1st October 2013 to 31st March 2014 for all cannabis-related presentations. Of 2198 presentations reported by 14 of the 16 Euro-DEN centres, 356 (16.2 %) involved cannabis either alone or together with other drugs/alcohol. There were 36 that involved lone use of cannabis (1.6 % of all presentations). Of the 35 non-fatal lone cannabis presentations, the most commonly reported features were neuro-behavioural (agitation/aggression 8 (22.9 %), psychosis 7 (20.0 %), anxiety 7 (20.0 %)) and vomiting 6 (17.1 %). Most patients (25, 71.4 %) received no treatment and 30 (85.7 %) were discharged/self-discharged from the ED. There was one fatality amongst these lone-cannabis cases: an 18-year-old male collapsed with an asystolic cardiac arrest whilst smoking cannabis and suffered hypoxic brain injury related to prolonged cardiac arrest. THC was detected in a urine sample taken at ED arrival; no other drugs were detected. Lone acute cannabis toxicity was typically associated with neuro-behavioural symptoms and vomiting. Although uncommon, severe toxicity including cardiovascular toxicity and death may be under-recognised, and it is important that Emergency Physicians are aware of this.
大麻是欧洲最常用的非法药物,通常被认为急性毒性较低。我们展示了欧洲药物急诊网络(Euro-DEN)项目前6个月关于大麻使用相关病例的数据收集结果,以进一步了解与大麻使用相关的急性毒性。从Euro-DEN最小数据集提取了2013年10月1日至2014年3月31日报告的所有大麻相关病例的急性娱乐性药物毒性的临床特征、治疗及转归数据。在Euro-DEN的16个中心中的14个报告的2198例病例中,356例(16.2%)单独或与其他药物/酒精一起涉及大麻。有36例单独使用大麻(占所有病例的1.6%)。在35例非致命性单独使用大麻的病例中,最常报告的特征是神经行为方面的(激越/攻击行为8例(22.9%)、精神病7例(20.0%)、焦虑7例(20.0%))和呕吐6例(17.1%)。大多数患者(25例,71.4%)未接受治疗,30例(85.7%)从急诊科出院/自行出院。在这些单独使用大麻的病例中有1例死亡:一名18岁男性在吸食大麻时因心脏停搏而晕倒,因长时间心脏停搏而遭受缺氧性脑损伤。在急诊科就诊时采集的尿液样本中检测到四氢大麻酚;未检测到其他药物。单独使用大麻的急性毒性通常与神经行为症状和呕吐有关。尽管不常见,但包括心血管毒性和死亡在内的严重毒性可能未得到充分认识,急诊医生了解这一点很重要。